Mark Mcdade, Director at Five Prime Therapeutics, holds 0.00 shares in Five Prime Therapeutics (Ticker: FPRX), holds 0.00 shares in Icosavax (Ticker: ICVX), holds 742.21K shares in Tourmaline Bio (Ticker: TRML). Most recently, Mark Mcdade ― shares of Five Prime Therapeutics on ― for an estimated value of ―.